HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL).

Date publication

octobre 2022

Journal

Clinical lymphoma, myeloma & leukemia

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier

Tous les auteurs :
Carlo-Stella C, Ansell S, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett N, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani R, Calmi P, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Eisen S, Negievich Y, Wang L, Wuerthner J, Herrera AF

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36164029

Résumé

Camidanlumab tesirine (Cami), an antibody-drug conjugate comprising a human IgG1 anti-CD25 monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer, displayed antitumor activity and manageable toxicity in a phase 1 trial in lymphoma, including R/R cHL (NCT02432235).

Mots clés

CD25, HL, Hodgkin lymphoma, Trial-in-Progress, antibody–drug conjugate, camidanlumab tesirine, clinical trial

Référence

Clin Lymphoma Myeloma Leuk. 2022 10;22 Suppl 2:S347